Preclinical data for CLYM116, anti-APRIL monoclonal antibody, highlight favorable pharmacokinetic and pharmacodynamic profile, supporting development for IgA nephropathy (IgAN) Long-term follow-up clinical data for budoprutug, anti-CD19 monoclonal antibody, support potential for therapeutic benefit in primary membranous nephropathy (pMN) WELLESLEY HILLS, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with ...

Core Viewpoint - Climb Bio, Inc. has appointed Susan Altschuller, Ph.D., MBA, as Chief Financial Officer, enhancing its leadership team to support the advancement of its therapeutic pipeline for immune-mediated diseases [1][2][3] Company Leadership - Susan Altschuller brings over 20 years of strategic and financial leadership experience in the biopharmaceutical sector, having previously served as CFO at Cerevel Therapeutics and ImmunoGen [2][3] - Her expertise includes financial strategy, capital allocation, and operational execution, which will be valuable as Climb Bio progresses with its clinical programs [2][3] Clinical Pipeline - Climb Bio is advancing two key programs: budoprutug, an anti-CD19 monoclonal antibody, and CLYM116, an anti-APRIL monoclonal antibody for IgA nephropathy [4] - The company anticipates generating significant clinical data from both programs in the upcoming year, which will inform future strategies [2][3] Inducement Equity Award - In connection with her appointment, Climb Bio granted Dr. Altschuller an inducement equity award consisting of a non-statutory stock option to purchase up to 600,000 shares of common stock, with a ten-year term and a four-year vesting schedule [3]

New preclinical data demonstrate deeper IgA reduction and a longer half-life compared to first-generation anti-APRIL monoclonal antibody CLYM116 Phase 1 trial initiation expected in Q4 2025, with initial biomarker and dosing interval data anticipated mid-year 2026 Company to host R&D Spotlight Webcast today, September 29, 2025 WELLESLEY HILLS, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, ...

Core Viewpoint - Climb Bio, Inc. is advancing its CLYM116 program, a preclinical-stage monoclonal antibody targeting APRIL for the treatment of IgA nephropathy, with a webcast event scheduled to discuss its potential and development strategy [1][2]. Company Overview - Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for immune-mediated diseases, with a pipeline that includes CLYM116 and budoprutug, an anti-CD19 monoclonal antibody [4]. CLYM116 Program Details - CLYM116 targets APRIL, a key driver of pathogenic B cell activity in autoimmune diseases, and employs a unique 'sweeper' mechanism to recycle the antibody and eliminate APRIL, potentially leading to best-in-class efficacy with less frequent dosing [2][5]. - The company plans to file an IND or CTA for CLYM116 in the second half of 2025, with a Phase 1 clinical trial to follow upon regulatory clearance [2][5]. Upcoming Webcast Event - The CLYM116 webcast event is scheduled for September 29, 2025, featuring Climb Bio's management and nephrologist Craig E. Gordon, and will be accessible via the company's website [1][3]. Research and Development Strategy - The event will cover an overview of IgA nephropathy, preclinical data comparing CLYM116 to a first-generation anti-APRIL monoclonal antibody, and the company's development strategy for CLYM116 [7].

Company Overview - Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for immune-mediated diseases [4] - The company's pipeline includes budoprutug, an anti-CD19 monoclonal antibody, and CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy [4] Upcoming Investor Conferences - Climb Bio's executive team will participate in several investor conferences in September 2025, including: - Cantor Global Healthcare Conference on September 5, 2025, at 10:55 a.m. ET in New York, NY [2] - Baird Global Healthcare Conference on September 9, 2025, at 4:20 p.m. ET in New York, NY [2] - Morgan Stanley Annual Global Healthcare Conference on September 10, 2025, with one-on-one meetings only [2] - Stifel Virtual Immunology and Inflammation Forum on September 16, 2025, at 10:30 a.m. ET, conducted virtually [3] Webcast Information - Live webcasts of the conferences will be accessible via the "Investors and News" section of the Climb Bio website, with replays available approximately two hours after each event and archived for at least 30 days [3]

Core Viewpoint - Climb Bio, Inc. is actively engaging with investors through participation in multiple upcoming healthcare conferences, showcasing its commitment to transparency and investor relations [1][2][3]. Group 1: Upcoming Conferences - Climb Bio will participate in the Cantor Global Healthcare Conference on September 5, 2025, featuring a fireside chat and one-on-one investor meetings [2]. - The company will also attend the Baird Global Healthcare Conference on September 9, 2025, with a similar format of fireside chat and one-on-one meetings [2]. - Additionally, Climb Bio is scheduled for the Morgan Stanley Annual Global Healthcare Conference on September 10, 2025, which will consist of one-on-one meetings only [2]. Group 2: Virtual Forum - Climb Bio will take part in the Stifel Virtual Immunology and Inflammation Forum on September 10, 2025, offering a presentation and one-on-one investor meetings [3]. - Live webcasts of these events will be accessible on the Climb Bio website, with replays available approximately two hours after each event and archived for at least 30 days [3]. Group 3: Company Overview - Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for immune-mediated diseases [4]. - The company's pipeline includes budoprutug, an anti-CD19 monoclonal antibody aimed at treating a range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy [4].

Core Insights - Climb Bio, Inc. is advancing its clinical pipeline with ongoing trials for budoprutug in immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE), and plans to initiate a trial for primary membranous nephropathy (pMN) soon [1][3][4] - The company has a strong financial position, with cash reserves expected to fund operations through 2027 [1][10] Budoprutug Program Updates - Budoprutug, an anti-CD19 monoclonal antibody, is currently in Phase 1b/2a trials for ITP and SLE, with enrollment ongoing [6][12] - The pMN Phase 2 trial is set to begin in the coming weeks, focusing on safety and preliminary efficacy [6][12] - A subcutaneous formulation of budoprutug has shown high bioavailability and favorable tolerability in non-clinical studies, with a Phase 1 trial expected to start shortly [1][6] CLYM116 Program Updates - CLYM116, an anti-APRIL monoclonal antibody, is progressing towards clinical development for IgA nephropathy (IgAN), with an IND or CTA submission anticipated in the second half of 2025 [5][14] - An investor event is planned for September 2025 to present new preclinical data on CLYM116 [1][5] Corporate Updates - Edgar D. Charles, M.D., MSc has been appointed as Chief Medical Officer, bringing over 20 years of experience in immunology-focused pharmaceutical development [8] - The company reported a net loss of $8.7 million for the second quarter of 2025, compared to a loss of $54.9 million in the same period of 2024 [10][19] Financial Highlights - As of June 30, 2025, Climb Bio had cash, cash equivalents, and marketable securities totaling $187.4 million [10][17] - Research and development expenses for the second quarter of 2025 were $6.6 million, significantly higher than $1.0 million in the same period of 2024 [10][19]

Core Insights - Climb Bio, Inc. has appointed Dr. Edgar D. Charles as Chief Medical Officer and Cindy J. Driscoll as Senior Vice President, Finance, enhancing its leadership team at a crucial time for the company [1][2] Leadership Appointments - Dr. Charles brings over 20 years of experience in immunology-focused pharmaceutical development, having previously held significant roles at Bristol Myers Squibb, where he led the development of various therapeutic candidates [2][3] - Cindy Driscoll has over two decades of experience in financial and administrative functions within the biopharma sector, previously serving as Senior Vice President of Finance at HC Bioscience [2][4] Clinical Development Focus - The company is focused on advancing its clinical studies for budoprutug and CLYM116, with Dr. Charles emphasizing the therapeutic potential of budoprutug in treating serious diseases where B cells are central to pathology [4][7] - Budoprutug is an anti-CD19 monoclonal antibody that has shown promise in B cell depletion, while CLYM116 is an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy [7] Inducement Equity Awards - Climb Bio has granted inducement equity awards to Dr. Charles and Ms. Driscoll, including stock options to purchase 600,000 and 200,000 shares of common stock, respectively, with an exercise price of $1.20 per share [5][6]

Core Points - Climb Bio, Inc. has granted an inducement equity award to a new employee as part of its 2025 Inducement Plan [1] - The inducement equity award consists of a non-statutory stock option for 120,000 shares at an exercise price of $1.27 per share, with a ten-year term and a four-year vesting schedule [2] - Climb Bio is focused on developing therapeutics for immune-mediated diseases, with a pipeline that includes budoprutug and CLYM116 [3] Summary by Category Inducement Equity Award - The inducement equity award was granted on May 19, 2025, to one new employee [2] - The stock option allows the purchase of up to 120,000 shares at an exercise price equal to the closing price on the grant date [2] - The vesting schedule includes 25% vesting on the first anniversary and the remainder vesting in 36 equal monthly installments [2] Company Overview - Climb Bio, Inc. is a clinical-stage biotechnology company [3] - The company is developing therapeutics for patients with immune-mediated diseases [3] - Key products in the pipeline include budoprutug, an anti-CD19 monoclonal antibody, and CLYM116, an anti-APRIL monoclonal antibody [3]

Core Insights - Climb Bio, Inc. is progressing towards initiating clinical trials for its lead product, budoprutug, targeting immune-mediated diseases, with trials expected to start in 2025 [1][2][3] - The company has a strong financial position, with cash reserves expected to last through 2027 [1][6] Clinical Development - Budoprutug, an anti-CD19 monoclonal antibody, is set to enter clinical studies for immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE) soon, with primary membranous nephropathy (pMN) trials expected in the second half of 2025 [2][3] - The FDA has granted clearance for Phase 2 trials of budoprutug in pMN and Phase 1b/2a trials in ITP, with plans for regulatory clearance for SLE trials outside the U.S. [3][4] - CLYM116, an anti-APRIL monoclonal antibody, is also in development, with preclinical data expected in the second half of 2025 and an IND submission anticipated by year-end [2][3][4] Financial Performance - As of March 31, 2025, the company reported cash, cash equivalents, and marketable securities totaling $197.8 million, down from $212.5 million at the end of 2024 [6][13] - Research and development expenses for Q1 2025 were $17.3 million, significantly higher than $1.1 million in Q1 2024, reflecting increased investment in clinical trials [6][13] - General and administrative expenses also rose to $5.7 million in Q1 2025 from $1.9 million in the same period last year [6][13] Leadership Changes - The company appointed Kim Cobleigh Drapkin and Bo Cumbo as independent directors, and Perrin Wilson, Ph.D., as Chief Business Officer, enhancing its leadership team with experienced professionals in biotechnology [1][9]